Astellas Pharma Aktie
9,53EUR | 0,08EUR | 0,85% |
WKN: 856273 / ISIN: JP3942400007
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 95,70 |
BlackRock Fund Advisors | 3,43 |
Nippon Life Insurance Co. | 2,85 |
Nomura Asset NEXT FUNDS TOPIX ETF (1306) | 2,84 |
Nomura Asset NEXT FUNDS NIKKEI 225 ETF (1321) | 2,46 |
BlackRock Japan Co. Ltd. | 2,10 |
Mitsubishi UFJ Asset Management Co., Ltd. | 1,58 |
Vanguard Health Care Fund | 1,57 |
Government Pension Fund - Global (The) | 1,53 |
Vanguard Total International Stock Index Fund | 1,38 |
Astellas Pharma Director Incentive Plan | 0,88 |
BlackRock Advisors (UK) Ltd. | 0,82 |
BlackRock Investment Management (UK) Ltd. | 0,51 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 15 883 | 15 455 | 14 522 | 14 484 | 14 754 |
Umsatz pro Mitarbeiter in Mio. EUR | 81,90 | 80,85 | 89,26 | 104,85 | 108,69 |
Bilanz (in Mio. JPY) - Aktiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 867 514 | 872 588 | 923 354 | 1 049 954 | 1 194 730 |
Summe Anlagevermögen | 1 450 646 | 1 401 040 | 1 409 041 | 1 406 564 | 2 374 873 |
Summe Aktiva | 2 318 160 | 2 273 628 | 2 332 395 | 2 456 518 | 3 569 603 |
Bilanz (in Mio. JPY) - Passiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 413 332 | 278 264 | 212 744 | 200 007 | 1 005 716 |
Summe Fremdkapital | 1 028 990 | 887 514 | 872 086 | 948 564 | 1 973 616 |
Summe Eigenkapital | 1 289 168 | 1 386 115 | 1 460 308 | 1 507 954 | 1 595 988 |
Summe Passiva | 2 318 158 | 2 273 629 | 2 332 394 | 2 456 518 | 3 569 604 |
Adresse
2-5-1 Nihonbashi-Honcho, 103-8411 Tokyo | |
Telefon | +81 (3) 3244-3000 |
Internet | https://www.astellas.com/jp/ |
Management
Adam John Pearson
Chief Strategy Officer |
Atsushi Kamide
Manager-Public Relations |
Catherine Levitt
General Counsel |
Claudia Mitchell
Senior VP-Product & Portfolio Strategy |
Claus Gerhard Zieler
Chief Commercial Officer |
Eriko Sakurai
Outside Director |
Haruko Shibumura
Outside Director |
Hideki Shima
Chief Manufacturing Officer |
Hideto Yamaguchi
Senior Director-Pharmaceutical Technologies |
Hiroko Sakai
Director |
Hiroo Sasaki
Outside Director |
Hiroshi Kawabe
Independent Outside Director |
Katsuyoshi Sugita
EVP, Chief People, Ethics & Compliance Officer |
Kazunori Maruyama
Director-Innovation Management |
Kei Motonaga
Sr Dir-Quality Control Div, Yaizu Technology Ctr |
Keisuke Mitsuoka
Associate Director |
Kenji Yasukawa
Chairman |
Kitamura Atsushi
Chief Financial Officer |
Luiz Dutra
Managing Director-Astellas Farma Brasil |
Mamoru Sekiyama
Independent Outside Director |
Masahide Goto
President-Astellas Institute-Regenerative Medicine |
Mika Nakayama
Outside Director |
Naoki Okamura
President, CEO & Representative Director |
Nick Eshkenazi
Chief Digital & Transformation Officer |
Nobuaki Tanaka
Senior Executive Officer & General Manager-Sales |
Nobue Yasuda
Manager-Accounting |
Noriyuki Uematsu
Outside Director |
Peter Sandor
VP, Head-Oncology Therapeutic Area in Mktg Strat |
Ryosuke Munakata
Director |
SUMIHO NAKATSU
Associate Manager |
Shigeru Nakaji
Exec Dir-Japan-Asia Clinical Dev 1, Dev |
Tadaaki Taniguchi
Chief Medical Officer |
Takashi Tanaka
Outside Director |
Taro Masunaga
Exec Dir-Incubation Rsch Labs, Drug Discovery Rsch |
Tatsuro Ishizuka
Independent Outside Director |
Tomokazu Fujisawa
Director |
Tomoyuki Yasunaga
Staff Exec Dir-Plnng & Admin-Drug Discovery Rsch |
Tyler Marciniak
Director-Oncology Communications & Advocacy |
Yoshitsugu Shitaka
Chief Scientific Officer & Head-Research |